Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers [0.03%]
核转运蛋白XPO1抑制剂增强KRAS G12C突变癌小鼠模型中抗癌药物的疗效
Husain Yar Khan,Misako Nagasaka,Yiwei Li et al.
Husain Yar Khan et al.
The identification of molecules that can bind covalently to KRAS G12C and lock it in an inactive GDP-bound conformation has opened the door to targeting KRAS G12C selectively. These agents have shown promise in preclinical tumor models and ...
The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways [0.03%]
眼附属器MALT淋巴瘤的遗传特征提示NFAT和MEF2B信号通路经常发生异常
Marco Magistri,Lanie E Happ,Jeremy Ramdial et al.
Marco Magistri et al.
A comprehensive constellation of somatic non-silent mutations and copy number (CN) variations in ocular adnexa marginal zone lymphoma (OAMZL) is unknown. By utilizing whole-exome sequencing in 69 tumors we define the genetic landscape of OA...
Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma [0.03%]
高剂量L-亚甲基四氢叶酸联合替莫唑胺和贝伐单抗治疗复发性IDH野生型高级别胶质瘤I期研究
Lucas A Salas,Thomas G Stewart,Bret C Mobley et al.
Lucas A Salas et al.
Purpose: IDH mutations in low-grade gliomas (LGGs) results in improved survival and DNA hypermethylation compared to IDH wild-type LGGs. IDH-mutant LGGs become hypomethylated during progression. It's uncertain if methylat...
HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma [0.03%]
HSP70抑制可阻断获得性耐药并可与MEK抑制联用治疗NRAS突变黑色素瘤
Joshua L D Parris,Thibaut Barnoud,Julia I-Ju Leu et al.
Joshua L D Parris et al.
NRAS-mutant melanoma is currently a challenge to treat. This is due to an absence of inhibitors directed against mutant NRAS, along with adaptive and acquired resistance of this tumor type to inhibitors in the MAPK pathway. Inhibitors to ME...
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics [0.03%]
肿瘤抑制物PLK2可作为三阴性乳腺癌的生物标志物以改善对PLK1治疗的反应
Yang Gao,Elena B Kabotyanski,Jonathan H Shepherd et al.
Yang Gao et al.
Polo-like kinase (PLK) family members play important roles in cell cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, frequent loss of chromosome 5q11-35 which ...
Sex- and mutation-specific p53 gain-of-function activity in gliomagenesis [0.03%]
p53获得性功能活性在胶质瘤发生中的性别和突变特异性研究
Nathan C Rockwell,Wei Yang,Nicole M Warrington et al.
Nathan C Rockwell et al.
In cancer, missense mutations in the DNA-binding domain of TP53 are common. They abrogate canonical p53 activity and frequently confer gain-of-oncogenic function (GOF) through localization of transcriptionally active mutant p53 to non-canon...
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition [0.03%]
通过CYP3A抑制有意调节伊布替尼的药代动力学性质
Eric D Eisenmann,Qiang Fu,Elizabeth M Muhowski et al.
Eric D Eisenmann et al.
Ibrutinib (Imbruvica; PCI-32765) is an orally administered inhibitor of Bruton's tyrosine kinase that has transformed the treatment of B-cell malignancies. However, ibrutinib has very low oral bioavailability that contributes to significant...
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers [0.03%]
Sotigalimab（CD40激动剂抗体）联合同期放化疗作为食管和胃食管交界处癌症新辅助治疗的II期研究
Purpose: Neoadjuvant chemoradiation (NCRT) followed by surgical resection represents a standard approach for patients with locally advanced esophageal/GEJ cancers. Sotigalimab is a high affinity CD40 agonist antibody capa...